Senesco Announces $3.0 Million Equity Financing

BRIDGEWATER, N.J. --(Business Wire)--

Senesco Technologies, Inc. ("Senesco" or the "Company") (OTCQB: SNTI)announced
today that it has entered into a securities purchase agreement to raise
approximately $3.0 million in gross proceeds through the sale of
30,000,000 shares of its common stock. The investors will also receive
100% warrant coverage at an exercise price of $0.12 per share. The
common stock and 100% warrant coverage (the "Unit") was priced at $0.10
per Unit.

The offering is expected to close on or about January 8, 2013. The net
proceeds of the financing will be used primarily for investor and public
relations, working capital, research and development and general
corporate purposes.

"We are very pleased to be able to supplement our capital resources in
order to advance the on-going Phase 1b/2a study and plan for the next
phase," said Leslie J. Browne, Ph.D., President and CEO of Senesco.

The shares and warrants are being offered pursuant to a prospectus
forming a part of the Company's effective registration statement (File
No. 333-170140) filed with the Securities and Exchange Commission (the
"SEC (News - Alert)"), a copy of which may be obtained, when available, at the SEC's
website at http://www.sec.gov.

This press release does not and shall not constitute an offer to sell or
the solicitation of an offer to buy, nor will there be any sale of these
securities in any state or jurisdiction in which such offer,
solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of any such state or
jurisdiction.

Additional terms of this offering (including the full terms and
conditios of the securities purchase agreement and warrants) were
disclosed on a Form 8-K filed with the SEC by Senesco simultaneously
with this press release and will also be disclosed in the prospectus
filed with the SEC in connection with this offering.

About SNS01-T

SNS01-T is a novel approach to cancer therapy that is designed to
selectively trigger apoptosis in B-cell cancers such as multiple
myeloma, and, mantle cell and diffuse large B-cell lymphomas. Senesco is
the sponsor of the Phase 1b/2a study that is actively enrolling patients
at Mayo Clinic in Rochester, MN, the University of Arkansas for Medical
Sciences in Little Rock, the Mary Babb Randolph Cancer Center in
Morgantown, WV, and the John Theurer Cancer Center at Hackensack
University Medical Center in Hackensack, NJ. http://www.clinicaltrials.gov/ct2/show/NCT01435720 term=SNS01-T&rank=1

About Senesco Technologies, Inc.

Senesco, a leader in eIF5A technology, is sponsoring a clinical study to
evaluate its lead therapeutic candidate SNS01-T in multiple myeloma,
diffuse large B-cell lymphoma and mantle cell lymphoma. SNS01-T targets
B-cell cancers and selectively induces apoptosis by modulating
eukaryotic translation initiation factor 5A (eIF5A), which is believed
to be an important regulator of cell growth and cell death. Accelerating
apoptosis may have applications in treating cancer, while delaying
apoptosis may have applications in treating certain inflammatory and
ischemic diseases. Senesco has already partnered with leading-edge
companies engaged in agricultural biotechnology and biofuels
development, and is entitled to earn research and development milestones
and royalties if its gene-regulating platform technology is incorporated
into its partners' commercialized products.

Forward-Looking Statements

Certain statements included in this press release are forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995. Actual results could differ materially from such
statements expressed or implied herein as a result of a variety of
factors, including, but not limited to: the Company's ability to
continue as a going concern; the Company's ability to recruit patients
for its clinical trial; the ability of the Company to consummate
additional financings; the development of the Company's gene technology;
the approval of the Company's patent applications; the successful
implementation of the Company's research and development programs and
collaborations; the success of the Company's license agreements; the
acceptance by the market of the Company's products; the timing and
success of the Company's preliminary studies, preclinical research and
clinical trials; competition and the timing of projects and trends in
future operating performance, as well as other factors expressed from
time to time in the Company's periodic filings with the Securities and
Exchange Commission (the "SEC"). As a result, this press release should
be read in conjunction with the Company's periodic filings with the SEC.
The forward-looking statements contained herein are made only as of the
date of this press release, and the Company undertakes no obligation to
publicly update such forward-looking statements to reflect subsequent
events or circumstances.